Intelligence · Clinical Development
Pipeline search results
Programs matching “alzheimer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 141 pipeline programs matching "alzheimer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
160701
Takeda
Alzheimer´s Disease
1 trial -
161003
Takeda
Alzheimer´s Disease
1 trial -
161202
Takeda
Alzheimer´s Disease
1 trial -
18F-AV-1451
The George Institute
Maladie d' Alzheimer, Alzheimer's pathology
1 trial -
20-AVP-786-306
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
ACP-204
Acadia Pharmaceuticals B.V.
Alzheimer's Disease Psychosis
2 trials -
ACP-204-008
Lacuna Pharma Pty Ltd
Alzheimer's Disease Psychosis
1 trial -
AVP-786 matching placebo, AVP-786
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
AXS-05
Axsome Therapeutics
Agitation in Patients With Dementia of the Alzheimer's Type
3 trials -
AXS-05 (dextromethorphan-bupropion)
Axsome Therapeutics
Agitation in Patients With Dementia of the Alzheimer's Type
2 trials -
Azeliragon
vTv Therapeutics
Alzheimer's Disease
1 trial -
Azeliragon 5mg
vTv Therapeutics
Alzheimer's Disease
1 trial -
C24-50
The George Institute
Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia
1 trial -
CN012-0023
Bristol-Myers Squibb Australia Pty Ltd
Agitation Associated with Alzheimer’s Disease
1 trial -
CN012-0024
Bristol-Myers Squibb Australia Pty Ltd
Agitation Associated with Alzheimer’s Disease
1 trial -
CN012-0025
Bristol-Myers Squibb Australia Pty Ltd
Agitation Associated with Alzheimer’s Disease
1 trial -
CN012-0051
Bristol-Myers Squibb Australia Pty Ltd
Mild to moderate Alzheimer’s Disease
1 trial -
CN012-0052
Bristol-Myers Squibb Australia Pty Ltd
Mild to moderate Alzheimer’s Disease
1 trial -
CN0120056
Bristol-Myers Squibb Australia Pty Ltd
Psychosis Associated with Alzheimer’s Disease
1 trial -
Crenezumab
Hoffmann-La Roche
Alzheimer's Disease
1 trial -
DEXMEDETOMIDINE , 18F-DPA-714
Pari Pharma GmbH
Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.
1 trial -
GV-971
Shanghai University of Traditional Chinese Medicine
Alzheimer Disease
1 trial -
Gantenerumab
Hoffmann-La Roche
Alzheimer Disease
1 trial -
I5T-MC-AACO
Eli Lilly Co.
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.